Institut Paoli-Calmettes Cancer Centre

The medical center is at the forefront of oncology research, particularly in the innovative use of Vascular Targeted Photodynamic Therapy (VTP) for treating Low-Grade Upper Tract Urothelial Cancer (UTUC). This approach leverages the unique properties of TOOKAD® (padeliporfin) to target and treat tumors located in the calyces, renal pelvis, and ureter.

• Vascular Targeted Photodynamic Therapy (VTP)
• Low-Grade Upper Tract Urothelial Cancer (UTUC)
• TOOKAD® (padeliporfin)

Through ongoing research, the center is contributing to the development of more effective and durable treatment options for patients with UTUC, enhancing both safety and efficacy in clinical applications.

Specializing in hematology, the center conducts pivotal research on Polycythemia Vera (PV), a type of myeloproliferative disorder. The focus is on comparing the efficacy of ruxolitinib against traditional therapies such as Hydroxycarbamide and interferon Alpha in managing high-risk PV patients.

• Polycythemia Vera (PV)
• Ruxolitinib
• Hydroxycarbamide and Interferon Alpha

The center's research aims to improve patient outcomes by reducing the incidence of major complications such as thrombosis, hemorrhage, and transformation to more severe conditions like Myelodysplastic syndrome and Acute Myeloid Leukemia.